Dyne Therapeutics (DYN)
Dyne Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
25.5M
Short interest
settlement 2026-10-15
7.4
Days to cover
-1.6 days vs prior
64.4%
Short share of volume
2026-11-03
3,492
Fails to deliver
settlement 2026-10-13
Wed 4 Nov
Next earnings
estimated date
-$65.6M
Insider flow, 90 days
1 buys, 15 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in DYN is 25,465,761 shares, up 2,084,714 shares over the last month. Over the last 48 readings it ranged from 9,402,823 shares (15 January 2025) to 25,977,390 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 3.4M shares a day that is 7.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/dyn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 25,465,761 | -2.0% | 3,444,276 | 7.39 |
| 2026-09-30 | 25,977,390 | +11.1% | 2,882,693 | 9.01 |
| 2026-09-15 | 23,381,047 | +12.5% | 4,280,444 | 5.46 |
| 2026-08-31 | 20,790,669 | -3.1% | 1,535,761 | 13.54 |
| 2026-08-14 | 21,459,799 | -2.3% | 1,960,545 | 10.95 |
| 2026-07-31 | 21,970,540 | +2.2% | 3,060,368 | 7.18 |
| 2026-07-15 | 21,491,180 | -3.6% | 2,019,028 | 10.64 |
| 2026-06-30 | 22,302,023 | -2.2% | 2,790,378 | 7.99 |
| 2026-06-15 | 22,812,489 | +2.4% | 1,591,982 | 14.33 |
| 2026-05-29 | 22,275,672 | +6.2% | 1,523,070 | 14.63 |
| 2026-05-15 | 20,983,648 | +1.2% | 1,251,838 | 16.76 |
| 2026-04-30 | 20,733,946 | -4.5% | 1,811,499 | 11.45 |
| 2026-04-15 | 21,704,095 | +6.0% | 1,615,478 | 13.44 |
| 2026-03-31 | 20,465,591 | +7.1% | 2,422,961 | 8.45 |
| 2026-03-13 | 19,103,364 | -1.1% | 2,899,945 | 6.59 |
| 2026-02-27 | 19,317,547 | +0.9% | 1,769,968 | 10.91 |
| 2026-02-13 | 19,152,510 | -0.2% | 1,662,304 | 11.52 |
| 2026-01-30 | 19,189,031 | +1.6% | 2,103,302 | 9.12 |
| 2026-01-15 | 18,889,124 | +9.2% | 2,269,509 | 8.32 |
| 2025-12-31 | 17,295,386 | +15.7% | 1,917,931 | 9.02 |
| 2025-12-15 | 14,949,400 | -14.4% | 4,208,510 | 3.55 |
| 2025-11-28 | 17,458,619 | +2.0% | 2,452,241 | 7.12 |
| 2025-11-14 | 17,111,938 | +13.2% | 2,624,140 | 6.52 |
| 2025-10-31 | 15,118,377 | -11.6% | 3,187,488 | 4.74 |
| 2025-10-15 | 17,097,410 | -3.8% | 2,311,080 | 7.40 |
| 2025-09-30 | 17,774,449 | +16.1% | 2,808,136 | 6.33 |
| 2025-09-15 | 15,303,535 | -4.6% | 2,003,038 | 7.64 |
| 2025-08-29 | 16,044,156 | -6.4% | 2,491,736 | 6.44 |
| 2025-08-15 | 17,141,207 | +5.1% | 3,544,045 | 4.84 |
| 2025-07-31 | 16,306,402 | +3.7% | 2,454,216 | 6.64 |
| 2025-07-15 | 15,730,352 | -3.9% | 4,146,941 | 3.79 |
| 2025-06-30 | 16,372,165 | -20.6% | 3,368,595 | 4.86 |
| 2025-06-13 | 20,621,906 | -19.2% | 2,271,539 | 9.08 |
| 2025-05-30 | 25,528,873 | +10.0% | 1,418,272 | 18.00 |
| 2025-05-15 | 23,198,935 | +56.1% | 3,423,451 | 6.78 |
| 2025-04-30 | 14,859,045 | -2.7% | 2,587,753 | 5.74 |
| 2025-04-15 | 15,267,942 | +34.6% | 3,104,776 | 4.92 |
| 2025-03-31 | 11,341,719 | -8.4% | 2,009,190 | 5.64 |
| 2025-03-14 | 12,383,217 | +6.1% | 1,677,169 | 7.38 |
| 2025-02-28 | 11,667,343 | +7.1% | 1,519,943 | 7.68 |
| 2025-02-14 | 10,895,395 | +14.0% | 1,543,390 | 7.06 |
| 2025-01-31 | 9,558,513 | +1.7% | 3,194,245 | 2.99 |
| 2025-01-15 | 9,402,823 | -10.6% | 2,554,795 | 3.68 |
| 2024-12-31 | 10,515,884 | +1.1% | 935,361 | 11.24 |
| 2024-12-13 | 10,399,800 | +0.5% | 742,047 | 14.02 |
| 2024-11-29 | 10,352,296 | +2.0% | 993,902 | 10.42 |
| 2024-11-15 | 10,152,544 | +2.1% | 1,253,906 | 8.10 |
| 2024-10-31 | 9,943,878 | +9.2% | 821,143 | 12.11 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of DYN volume is 64.4%, up 16.1 points over the last five sessions. Over the last 30 readings it ranged from 38.5% (20 October 2026) to 78.0% (9 October 2026). The latest reading is 6.5 points above the 30-session average of 57.9%, on 856K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 551K | 856K | 64.4% | 8,800 |
| 2026-11-02 | 524K | 892K | 58.7% | 0 |
| 2026-10-30 | 291K | 576K | 50.4% | 0 |
| 2026-10-29 | 329K | 573K | 57.5% | 10,296 |
| 2026-10-28 | 345K | 784K | 44.0% | 0 |
| 2026-10-27 | 615K | 1.3M | 48.3% | 114 |
| 2026-10-26 | 439K | 659K | 66.7% | 0 |
| 2026-10-23 | 492K | 703K | 70.0% | 0 |
| 2026-10-22 | 341K | 775K | 44.0% | 406 |
| 2026-10-21 | 406K | 726K | 55.9% | 0 |
| 2026-10-20 | 585K | 1.5M | 38.5% | 600 |
| 2026-10-19 | 1.2M | 1.9M | 62.3% | 9,710 |
| 2026-10-16 | 653K | 1.1M | 58.9% | 4,546 |
| 2026-10-15 | 428K | 727K | 58.8% | 9,324 |
| 2026-10-14 | 420K | 848K | 49.5% | 934 |
| 2026-10-13 | 703K | 1.4M | 51.9% | 58 |
| 2026-10-12 | 585K | 1.1M | 54.5% | 431 |
| 2026-10-09 | 806K | 1.0M | 78.0% | 805 |
| 2026-10-08 | 1.2M | 1.7M | 70.4% | 11,865 |
| 2026-10-07 | 821K | 1.3M | 64.8% | 5 |
| 2026-10-06 | 945K | 1.8M | 53.3% | 31 |
| 2026-10-05 | 1.1M | 2.1M | 53.7% | 0 |
| 2026-10-02 | 369K | 879K | 42.0% | 0 |
| 2026-10-01 | 747K | 1.4M | 54.4% | 54 |
| 2026-09-30 | 1.1M | 1.7M | 64.9% | 465 |
| 2026-09-29 | 457K | 817K | 56.0% | 6,801 |
| 2026-09-28 | 607K | 972K | 62.4% | 0 |
| 2026-09-25 | 378K | 532K | 71.1% | 1,262 |
| 2026-09-24 | 811K | 1.2M | 69.0% | 0 |
| 2026-09-23 | 628K | 1000K | 62.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in DYN is 3,492 shares, down 5,948 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (11 May 2026) to 263,431 shares (22 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 3,492 | $15.96 | $56K |
| 2026-10-09 | 9,440 | $16.37 | $155K |
| 2026-10-01 | 3,114 | $16.11 | $50K |
| 2026-09-22 | 580 | $17.12 | $10K |
| 2026-09-14 | 2,345 | $18.21 | $43K |
| 2026-09-11 | 21 | $18.42 | $387 |
| 2026-09-09 | 131 | $20.31 | $3K |
| 2026-08-20 | 4 | $26.78 | $107 |
| 2026-08-18 | 10 | $26.15 | $262 |
| 2026-07-31 | 55,528 | $25.73 | $1.4M |
| 2026-07-28 | 312 | $25.63 | $8K |
| 2026-07-23 | 19 | $23.21 | $441 |
| 2026-07-22 | 43 | $23.83 | $1K |
| 2026-07-21 | 559 | $23.45 | $13K |
| 2026-07-17 | 581 | $22.72 | $13K |
| 2026-07-14 | 3,399 | $23.64 | $80K |
| 2026-07-13 | 2,202 | $23.42 | $52K |
| 2026-07-01 | 75,144 | $22.21 | $1.7M |
| 2026-06-30 | 162 | $21.26 | $3K |
| 2026-06-22 | 263,431 | $19.80 | $5.2M |
| 2026-06-12 | 2,829 | $17.95 | $51K |
| 2026-06-10 | 71 | $17.92 | $1K |
| 2026-06-08 | 36,267 | $17.04 | $618K |
| 2026-06-03 | 1,353 | $17.24 | $23K |
| 2026-06-01 | 96 | $19.33 | $2K |
| 2026-05-26 | 2 | $17.37 | $35 |
| 2026-05-20 | 8,179 | $15.92 | $130K |
| 2026-05-12 | 3,497 | $18.46 | $65K |
| 2026-05-11 | 1 | $17.61 | $18 |
| 2026-05-07 | 5 | $18.84 | $94 |
Insider trades
SEC Form 4, newest first. JSONOver the last 90 days DYN insiders reported 1 open-market buy ($40K) against 15 sells ($65.7M), so the dollar flow leans toward selling. Latest filing: Kerr Douglas (Head of R&D and CMO) on 2026-10-20.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Kerr Douglas | Head of R&D and CMO | Grant | 8K | $0.00 | $0 | 171K |
| 2026-10-02 | Posner Brian S | Director | Buy | 3K | $16.00 | $40K | 27K |
| 2026-09-08 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 185 | $18.88 | $3K | 153K |
| 2026-09-08 | Kerr Douglas | Chief Medical Officer | Sell | 1K | $18.88 | $24K | 163K |
| 2026-09-08 | Cox John | CEO & President | Sell | 6K | $18.88 | $107K | 358K |
| 2026-09-04 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 900 | $24.35 | $22K | 153K |
| 2026-09-04 | Kerr Douglas | Chief Medical Officer | Sell | 4K | $24.35 | $91K | 164K |
| 2026-08-14 | Rhodes Jason P | Director | Sell | 322K | $25.00 | $8.1M | 429K |
| 2026-08-14 | Rhodes Jason P | Director | Sell | 478K | $25.00 | $12.0M | 567K |
| 2026-08-14 | Rhodes Jason P | Director | Sell | 1.4M | $25.00 | $34.0M | 2.4M |
| 2026-08-13 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 226 | $26.28 | $6K | 154K |
| 2026-08-13 | Kerr Douglas | Chief Medical Officer | Sell | 2K | $26.28 | $41K | 168K |
| 2026-08-13 | Lucera Erick | Chief Financial Officer | Sell | 2K | $26.28 | $47K | 120K |
| 2026-08-13 | Rhodes Jason P | Director | Sell | 64K | $26.20 | $1.7M | 751K |
| 2026-08-13 | Rhodes Jason P | Director | Sell | 94K | $26.20 | $2.5M | 1.0M |
| 2026-08-13 | Rhodes Jason P | Director | Sell | 268K | $26.20 | $7.0M | 3.8M |
| 2026-08-13 | Cox John | CEO & President | Sell | 5K | $26.28 | $131K | 363K |
| 2026-07-27 | Kersten Dirk | Director | Sell | 5K | $26.04 | $140K | 3.6M |
| 2026-07-27 | Kersten Dirk | Director | Sell | 256K | $25.50 | $6.5M | 3.6M |
| 2026-07-07 | Rhodes Jason P | Director | Sell | 5K | $23.61 | $118K | 3K |
| 2026-07-07 | Rhodes Jason P | Director | Sell | 12K | $23.62 | $276K | 815K |
| 2026-07-07 | Rhodes Jason P | Director | Sell | 49K | $23.17 | $1.1M | 827K |
| 2026-07-07 | Rhodes Jason P | Director | Sell | 15K | $23.62 | $351K | 1.1M |
| 2026-07-07 | Rhodes Jason P | Director | Sell | 63K | $23.17 | $1.4M | 1.2M |
| 2026-07-07 | Rhodes Jason P | Director | Sell | 30K | $23.62 | $699K | 4.1M |
| 2026-07-07 | Rhodes Jason P | Director | Sell | 124K | $23.17 | $2.9M | 4.1M |
| 2026-07-06 | Rhodes Jason P | Director | Sell | 100K | $22.79 | $2.3M | 876K |
| 2026-07-06 | Rhodes Jason P | Director | Sell | 127K | $22.79 | $2.9M | 1.2M |
| 2026-07-06 | Rhodes Jason P | Director | Sell | 253K | $22.79 | $5.8M | 4.2M |
| 2026-06-29 | Rhodes Jason P | Director | Sell | 52K | $21.14 | $1.1M | 1.3M |
| 2026-06-29 | Rhodes Jason P | Director | Sell | 41K | $21.14 | $860K | 976K |
| 2026-06-29 | Rhodes Jason P | Director | Sell | 103K | $21.14 | $2.2M | 4.5M |
| 2026-06-26 | Rhodes Jason P | Director | Sell | 64K | $21.28 | $1.4M | 1.0M |
| 2026-06-26 | Rhodes Jason P | Director | Sell | 82K | $21.28 | $1.7M | 1.4M |
| 2026-06-26 | Rhodes Jason P | Director | Sell | 163K | $21.28 | $3.5M | 4.6M |
| 2026-06-25 | Rhodes Jason P | Director | Sell | 5K | $21.10 | $106K | 1.1M |
| 2026-06-25 | Rhodes Jason P | Director | Sell | 13K | $21.10 | $268K | 4.7M |
| 2026-06-25 | Rhodes Jason P | Director | Sell | 6K | $21.10 | $135K | 1.5M |
| 2026-06-25 | Lucera Erick | Chief Financial Officer | Sell | 2K | $20.37 | $48K | 122K |
| 2026-06-24 | Rhodes Jason P | Director | Sell | 51K | $21.02 | $1.1M | 4.8M |
| 2026-06-24 | Rhodes Jason P | Director | Sell | 25K | $21.02 | $534K | 1.5M |
| 2026-06-24 | Rhodes Jason P | Director | Sell | 20K | $21.02 | $420K | 1.1M |
| 2026-06-23 | Kersten Dirk | Director | Sell | 72K | $21.04 | $1.5M | 3.8M |
| 2026-06-23 | Kersten Dirk | Director | Sell | 2K | $21.47 | $36K | 3.8M |
| 2026-06-23 | Rhodes Jason P | Director | Sell | 39K | $21.13 | $827K | 1.5M |
| 2026-06-23 | Rhodes Jason P | Director | Sell | 78K | $21.13 | $1.6M | 4.8M |
| 2026-06-23 | Rhodes Jason P | Director | Sell | 31K | $21.13 | $650K | 1.1M |
| 2026-06-22 | Kersten Dirk | Director | Sell | 191K | $20.57 | $3.9M | 3.9M |
| 2026-06-18 | Kersten Dirk | Director | Sell | 47K | $20.07 | $941K | 4.1M |
| 2026-06-17 | Kersten Dirk | Director | Sell | 37K | $20.14 | $754K | 4.2M |
| 2026-06-16 | Cox John | CEO & President | Sell | 3K | $18.33 | $49K | 368K |
| 2026-06-16 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 145 | $18.33 | $3K | 154K |
| 2026-06-16 | Kerr Douglas | Chief Medical Officer | Sell | 887 | $18.33 | $16K | 169K |
| 2026-06-08 | Posner Brian S | Director | Buy | 2K | $16.94 | $34K | 25K |
| 2026-06-03 | Posner Brian S | Director | Buy | 3K | $17.48 | $44K | 23K |
| 2026-05-26 | Posner Brian S | Director | Buy | 2K | $18.21 | $36K | 20K |
| 2026-05-20 | Posner Brian S | Director | Buy | 3K | $17.12 | $43K | 18K |
| 2026-05-13 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 228 | $18.36 | $4K | 154K |
| 2026-05-13 | Kerr Douglas | Chief Medical Officer | Sell | 2K | $18.36 | $29K | 170K |
| 2026-05-13 | Lucera Erick | Chief Financial Officer | Sell | 1K | $18.36 | $27K | 124K |
| 2026-05-13 | Cox John | CEO & President | Sell | 3K | $18.36 | $61K | 371K |
| 2026-05-06 | Rhodes Jason P | Director | Sell | 17K | $18.18 | $313K | 1.1M |
| 2026-05-06 | Rhodes Jason P | Director | Sell | 428 | $18.18 | $8K | 8K |
| 2026-05-06 | Rhodes Jason P | Director | Sell | 44K | $18.18 | $793K | 4.9M |
| 2026-05-06 | Rhodes Jason P | Director | Sell | 22K | $18.18 | $399K | 1.5M |
| 2026-05-05 | Rhodes Jason P | Director | Sell | 2K | $18.03 | $43K | 1.2M |
| 2026-05-05 | Rhodes Jason P | Director | Sell | 60 | $18.03 | $1K | 8K |
| 2026-05-05 | Rhodes Jason P | Director | Sell | 6K | $18.03 | $110K | 4.9M |
| 2026-05-05 | Rhodes Jason P | Director | Sell | 3K | $18.03 | $55K | 1.6M |
| 2026-05-04 | Rhodes Jason P | Director | Sell | 2K | $18.00 | $44K | 1.2M |
| 2026-05-04 | Rhodes Jason P | Director | Sell | 61 | $18.00 | $1K | 8K |
| 2026-05-04 | Rhodes Jason P | Director | Sell | 6K | $18.00 | $112K | 4.9M |
| 2026-05-04 | Rhodes Jason P | Director | Sell | 3K | $18.00 | $56K | 1.6M |
| 2026-04-28 | Rhodes Jason P | Director | Sell | 21 | $19.00 | $399 | 1.2M |
| 2026-04-28 | Rhodes Jason P | Director | Sell | 1 | $19.00 | $19 | 9K |
| 2026-04-28 | Rhodes Jason P | Director | Sell | 52 | $19.00 | $988 | 4.9M |
| 2026-04-28 | Rhodes Jason P | Director | Sell | 26 | $19.00 | $494 | 1.6M |
| 2026-04-28 | Rhodes Jason P | Director | Sell | 47K | $18.38 | $865K | 1.2M |
| 2026-04-28 | Rhodes Jason P | Director | Sell | 1K | $18.38 | $22K | 9K |
| 2026-04-28 | Rhodes Jason P | Director | Sell | 119K | $18.38 | $2.2M | 4.9M |
| 2026-04-28 | Rhodes Jason P | Director | Sell | 60K | $18.38 | $1.1M | 1.6M |
| 2026-04-27 | Rhodes Jason P | Director | Sell | 36K | $18.15 | $652K | 1.2M |
| 2026-04-27 | Rhodes Jason P | Director | Sell | 894 | $18.15 | $16K | 10K |
| 2026-04-27 | Rhodes Jason P | Director | Sell | 91K | $18.15 | $1.7M | 5.1M |
| 2026-04-27 | Rhodes Jason P | Director | Sell | 46K | $18.15 | $830K | 1.6M |
| 2026-04-24 | Rhodes Jason P | Director | Sell | 29K | $18.48 | $528K | 1.2M |
| 2026-04-24 | Rhodes Jason P | Director | Sell | 710 | $18.48 | $13K | 11K |
| 2026-04-24 | Rhodes Jason P | Director | Sell | 72K | $18.48 | $1.3M | 5.1M |
| 2026-04-24 | Rhodes Jason P | Director | Sell | 36K | $18.48 | $672K | 1.7M |
| 2026-04-24 | Lubner David Charles | Director | Gift | 54K | $0.00 | $0 | 0 |
| 2026-04-23 | Rhodes Jason P | Director | Sell | 15K | $19.19 | $291K | 1.3M |
| 2026-04-23 | Rhodes Jason P | Director | Sell | 377 | $19.19 | $7K | 11K |
| 2026-04-23 | Rhodes Jason P | Director | Sell | 38K | $19.19 | $735K | 5.2M |
| 2026-04-23 | Rhodes Jason P | Director | Sell | 19K | $19.19 | $370K | 1.7M |
| 2026-04-22 | Rhodes Jason P | Director | Sell | 60K | $19.68 | $1.2M | 1.3M |
| 2026-04-22 | Rhodes Jason P | Director | Sell | 1K | $19.68 | $29K | 12K |
| 2026-04-22 | Rhodes Jason P | Director | Sell | 151K | $19.68 | $3.0M | 5.3M |
| 2026-04-22 | Rhodes Jason P | Director | Sell | 76K | $19.68 | $1.5M | 1.7M |
| 2026-04-22 | Kersten Dirk | Director | Sell | 3K | $20.00 | $53K | 4.2M |
| 2026-04-21 | Rhodes Jason P | Director | Sell | 605 | $20.05 | $12K | 1.3M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON18 Form 144 notices on file for DYN worth $44.2M at the prices reported; 6 in the last 90 days worth $472K. Latest: Kerr Douglas filed on 2026-09-08 to sell 35 shares ($661) from 2026-09-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-08 | Kerr DouglasOfficer | 35 | $661 | 0.000% | 2026-09-08 | Stifel Nicolaus & Company Inc |
| 2026-09-08 | Cox JohnOfficer | 6K | $107K | 0.003% | 2026-09-08 | Stifel Nicolaus & Company Inc |
| 2026-09-04 | Kerr DouglasOfficer | 5K | $122K | 0.003% | 2026-09-04 | Stifel Nicolaus & Company Inc |
| 2026-08-13 | Lucera ErickOfficer | 2K | $47K | 0.001% | 2026-08-13 | Stifel Nicolaus & Company Inc |
| 2026-08-13 | Kerr DouglasOfficer | 2K | $64K | 0.001% | 2026-08-13 | Stifel Nicolaus & Company Inc |
| 2026-08-13 | Cox JohnOfficer | 5K | $131K | 0.003% | 2026-08-13 | Stifel Nicolaus & Company Inc |
| 2026-07-27 | ForDyne B.V.Affiliate | 261K | $6.7M | 0.158% | 2026-07-27 | UBS Financial Services Inc. |
| 2026-06-25 | Lucera ErickOfficer | 2K | $48K | 0.001% | 2026-06-25 | Stifel Nicolaus & Company Inc |
| 2026-06-17 | ForDyne B.V.Affiliate | 348K | $6.4M | 0.211% | 2026-06-17 | UBS Financial Services Inc. |
| 2026-06-16 | Cox JohnOfficer | 3K | $49K | 0.002% | 2026-06-16 | Stifel Nicolaus & Company Inc |
| 2026-05-13 | Lucera ErickOfficer | 1K | $27K | 0.001% | 2026-05-13 | Stifel Nicolaus & Company Inc |
| 2026-05-13 | Cox JohnOfficer | 3K | $61K | 0.002% | 2026-05-13 | Stifel Nicolaus & Company Inc |
| 2026-04-01 | Lucera ErickOfficer | 6K | $107K | 0.003% | 2026-04-01 | Stifel Nicolaus & Company Inc |
| 2026-03-11 | ForDyne B.V.Affiliate | 807K | $15.9M | 0.489% | 2026-03-11 | UBS Financial Services Inc. |
| 2026-03-09 | ForDyne B.V.Affiliate | 807K | $14.3M | 0.489% | 2026-03-09 | UBS Financial Services Inc. |
| 2026-03-05 | Cox JohnOfficer | 3K | $41K | 0.002% | 2026-03-05 | Stifel Nicolaus & Company Inc |
| 2025-12-05 | Kerr DouglasOfficer | 880 | $18K | 0.001% | 2025-12-05 | Stifel Nicolaus & Company Inc |
| 2025-12-05 | Cox JohnOfficer | 3K | $55K | 0.002% | 2025-12-05 | Stifel Nicolaus & Company Inc |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of DYN in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 18.7% of the class (30,785,801 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Fund XI, L.P.partnership | 4.5M | 2.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates XI, L.P.partnership | 4.5M | 2.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates XI, LLCother entity | 4.5M | 2.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates Opportunity II, LLCother entity | 1.3M | 0.7% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Opportunity Fund II, L.P.partnership | 1.3M | 0.7% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates Opportunity II, L.P.partnership | 1.3M | 0.7% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates Opportunity I, LLCother entity | 976K | 0.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Associates Opportunity I, L.P.partnership | 976K | 0.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 6 | Atlas Venture Opportunity Fund I, L.P.partnership | 976K | 0.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 7 | JANUS HENDERSON GROUP Ltd.parent holding company | 12.0M | 7.3% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 1 | FMR LLCparent holding company | 11.2M | 6.8% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 11.2M | 6.8% | 2026-06-30 |
| 2026-07-28 | 13G/Ano. 3 | BlackRock, Inc.parent holding company | 11.5M | 7.0% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 2 | T. Rowe Price Investment Management, Inc.investment adviser | 30.8M | 18.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 6 | JANUS HENDERSON GROUP PLCparent holding company | 13.6M | 8.3% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-11-14 | 13G/Ano. 3 | Peter Kolchinskyparent holding company, individual | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | Rajeev Shahparent holding company, individual | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | RA Capital Healthcare Fund, L.P.partnership | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | RA Capital Management, L.P.investment adviser, partnership | 0 | 0.0% | 2025-09-30 |
13F holders
Tracked managers holding DYN at their latest 13F. JSON7 of the 30 tracked managers held DYN at their latest 13F, $53.2M in total at quarter-end prices. Citadel Advisors is the largest at $25.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 1.1M | $25.4M | 0.00% | +943K |
| Millennium Management | 2026-06-30 | 432K | $9.6M | 0.00% | +273K |
| Renaissance Technologies | 2026-06-30 | 361K | $8.0M | 0.01% | -173K |
| Fisher Asset Management | 2026-06-30 | 299K | $6.6M | 0.00% | -25K |
| AQR Capital Management | 2026-06-30 | 84K | $1.9M | 0.00% | -184 |
| D. E. Shaw & Co. | 2026-06-30 | 60K | $1.3M | 0.00% | new |
| Two Sigma Investments | 2026-06-30 | 14K | $315K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$403.2M of operating cash flow. As of 2026-06-30, cash was $676.1M against $199.3M of debt.
- Cash
- $676.1M
- Debt
- $199.3M
- Equity
- $702.2M
- Total assets
- $994.0M
- Shares outstanding
- 186,746,431
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$178.6M | n/a | -1.08 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$120.9M | n/a | -0.73 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$112.0M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$108.0M | n/a | -0.76 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$110.9M | n/a | -0.97 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$115.4M | n/a | -1.05 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$89.5M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$97.1M | n/a | -0.96 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$446.2M | -$403.2M | $1.9M | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$317.4M | -$292.4M | $2.4M | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$235.9M | -$188.2M | $729K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$168.1M | -$153.6M | $3.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$149.3M | -$119.6M | $3.6M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-24 from the cover page.
What this page is
Dyne Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Dyne Therapeutics (DYN), SEC CIK 1818794, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-08.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-29.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-20.JSON and CSV
- Company record
- EDGAR filing index for CIK 1818794Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of DYN is sold short?
25,465,761 shares were held short at the 2026-10-15 settlement, 7.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is DYN's daily short volume?
On 2026-11-03, 551,135 of the 856,153 DYN shares reported to FINRA were sold short, 64.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does DYN have fails to deliver?
The SEC's latest file shows 3,492 DYN shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are DYN insiders buying or selling?
Over the last 90 days DYN insiders reported 1 open-market buy ($40K) against 15 sells ($65.7M), so the dollar flow leans toward selling. Latest filing: Kerr Douglas (Head of R&D and CMO) on 2026-10-20.
Have DYN insiders filed to sell?
18 Form 144 notices on file for DYN worth $44.2M at the prices reported; 6 in the last 90 days worth $472K. Latest: Kerr Douglas filed on 2026-09-08 to sell 35 shares ($661) from 2026-09-08.
Who owns 5% or more of DYN?
6 holders report 5% or more of DYN in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 18.7% of the class (30,785,801 shares), filed 2026-05-15 for an event on 2026-03-31.
What did DYN report last quarter?
In FY 2025 it generated -$403.2M of operating cash flow. As of 2026-06-30, cash was $676.1M against $199.3M of debt.
Which tracked 13F managers own DYN?
7 of the 30 tracked 13F managers held DYN shares at their latest filing, $53.2M in all. The largest: Ken Griffin's Citadel Advisors (1.1M shares, $25.4M), Izzy Englander's Millennium Management (432K shares, $9.6M), Renaissance Technologies (361K shares, $8.0M), Ken Fisher's Fisher Asset Management (299K shares, $6.6M), Cliff Asness's AQR Capital Management (84K shares, $1.9M), D. E. Shaw & Co. (60K shares, $1.3M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.